№ lp_1_22028
File format: docx
Character count: 5599
File size: 146 KB
Year:
2024
Region / city:
Victoria, Australia
Topic:
Urinary Tract Infection Treatment
Document Type:
Patient Handout
Organ / Institution:
Department of Health, Victoria
Author:
Department of Health, Victoria
Target Audience:
Women and gender diverse people with female biology aged 18-65
Period of validity:
March 2024
Approval date:
March 2024
Date of amendments:
N/A
Contextual Description:
Patient handout providing details about treatment, eligibility, and self-care for uncomplicated urinary tract infection under a pilot program for community pharmacists.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Region / city:
Victoria, Australia
Topic:
Health, Urinary Tract Infection, Pharmacist Services
Document type:
Patient handout
Author:
Department of Health, Victoria Government
Target audience:
Women and gender diverse people with female biology aged 18-65, including Medicare and international students
Period of validity:
December 2025
Approval date:
December 2025
Date of updates:
Not specified
Year:
Not specified
Region / City:
Not specified
Subject:
Acute uncomplicated urinary tract infection (UTI) treatment
Document Type:
Patient Group Direction (PGD)
Author:
Not specified
Target Audience:
Healthcare professionals, community pharmacy staff
Effective Period:
Not specified
Approval Date:
Not specified
Revision Date:
Not specified
Year:
2023
Region:
Western Australia
Type of document:
Structured Administration and Supply Arrangement (SASA)
Authority:
Chief Executive Officer of Health under Part 6 of the Medicines and Poisons Regulations 2016
Issuer:
Dr Andrew Robertson, Chief Health Officer, Department of Health WA
Practitioner:
Registered Pharmacists with approved training
Practice setting:
Registered community pharmacies in Western Australia
Approved activity:
Supply of Schedule 4 oral antibiotics for uncomplicated urinary tract infection
Approved medicines:
Nitrofurantoin, Trimethoprim
Target population:
Female patients aged 18–65 with uncomplicated UTI
Conditions:
Compliance with training, registration, clinical criteria, record-keeping, and regulatory requirements
Date issued:
24 July 2023
Contact:
Medicines and Poisons Regulation Branch, [email protected]
Note:
, Number 034/7-2023
Year:
N/A
Region / City:
N/A
Subject:
Acute Urinary Tract Infection Treatment
Document Type:
Patient Group Direction
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Healthcare professionals, pharmacists
Effective Period:
N/A
Approval Date:
N/A
Amendment Date:
N/A
Year:
2025
Region / city:
Victoria, Australia
Topic:
Health, Urinary Tract Infection, Pharmacist Services
Document type:
Patient handout
Author:
Department of Health, Victoria Government
Target audience:
Women and gender diverse people with female biology aged 18-65, including Medicare and international students
Period of validity:
December 2025
Approval date:
December 2025
Date of updates:
Not specified
Year:
2023
Region / City:
New Zealand
Subject:
Medical referral for Stress Urinary Incontinence (SUI) treatment
Document Type:
Medical Referral Form
Institution:
Manatū Hauora (Health Ministry)
Author:
Not specified
Target Audience:
Healthcare professionals (Referring clinicians, specialists)
Period of Application:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Description:
Form for referring patients with stress urinary incontinence for multidisciplinary discussion and evaluation, including medical history, symptoms, diagnostic tests, and treatment options.
Year:
2024
Region / City:
Wales
Topic:
Healthcare, Pharmacy, Urinary Tract Infection
Document Type:
Patient Group Directions (PGD)
Organisation:
Welsh Medicines Advice Service, NHS Wales
Author:
Dianne Burnett, Louise Allen, Emlyn Pritchard, Adam Mackridge, Richard Coulthard
Target Audience:
Healthcare professionals, community pharmacists
Validity Period:
From 03 June 2024 to 02 June 2027
Approval Date:
22 April 2024
Ratification Date:
09 May 2024
Review Date:
08 February 2027
Expiry Date:
02 June 2027
Version:
1.0
Change History:
Version 1.0 developed on 22 December 2023
Clinical Condition:
Acute, uncomplicated lower urinary tract infection
Treatment:
Nitrofurantoin, Trimethoprim
Applicable Group:
Non-pregnant females or transgender males (16-64 years)
Authorising Organisation:
Local Health Board
Staff Requirements:
Registered pharmacists, authorised by name
Retention Period:
8 years for adults, 25 years for children
Local Inquiries:
[insert local details]
Note:
Year
Subject:
Healthcare Plan, Risk Management
Document Type:
Healthcare Plan
Target Audience:
Individuals at risk of urinary tract infections
Year:
2023
Region / City:
Canberra
Topic:
Healthcare Procedure
Document Type:
Procedure Manual
Organization:
Canberra Health Services
Author:
Not specified
Target Audience:
Healthcare professionals (nurses, doctors, allied health staff)
Period of validity:
Ongoing
Approval Date:
Not specified
Date of Amendments:
Not specified
Year:
2022
Region / city:
United Kingdom
Topic:
Healthcare, Infectious Diseases, Antimicrobial Resistance
Document Type:
Briefing Paper
Organization / Institution:
National Institute for Health and Care Excellence
Author:
NICE
Target Audience:
Healthcare professionals, Policy makers, Researchers
Period of validity:
Not specified
Approval Date:
12th July 2022
Date of Changes:
Not specified
Year:
2022
Region / city:
United Kingdom
Subject:
Health care, Medical guidelines
Document type:
Quality standard
Organization / institution:
National Institute for Health and Care Excellence (NICE)
Author:
National Institute for Health and Care Excellence (NICE)
Target audience:
Healthcare professionals, Service providers
Period of validity:
2022-2023
Approval date:
11 June 2015
Date of amendments:
6 September 2022
Note:
Contextual description
Version:
2.0
Year:
2025
Region / city:
[location/service/organisation]
Topic:
Urinary Tract Infection, Nitrofurantoin, PGD (Patient Group Direction)
Document type:
PGD (Patient Group Direction)
Organization:
UKHSA
Author:
Dr. Diane Ashiru-Oredope, Dr. Imran Jawaid, Dr. Kiren Collison, Dr. Naomi Fleming, Mandy Slatter, Jo Jenkins, Kieran Reynolds, Liz Cross, Professor Bhaskar Somani, Temitope Odetunde, Tracy Rogers
Target audience:
Registered healthcare professionals authorized by their organization
Effective date:
1st January 2026
Review date:
30th June 2028
Expiry date:
31st December 2028
Approval body:
UKHSA HCAI & AMR Division
Document version history:
1.0 (January 2023), 1.1 (July 2023), 1.2 (February 2024), 1.3 (April 2024), 1.4 (January 2025), 2.0 (October 2025)
PGD reviewed by:
National UTI antimicrobial PGD Short Life Working Group
Context:
This document outlines a Patient Group Direction for the use of nitrofurantoin in the treatment of urinary tract infections, specifying authorized practitioners and legal requirements.
Year:
2021
Region/Country:
United Arab Emirates
Type of document:
Clinical guideline
Organization:
National Antimicrobial Stewardship Committee
Target population:
Adult outpatients, Adult inpatients, Pregnant women
Scope:
Empiric antibiotic management of urinary tract infections
Version:
1
Date of issue:
1 September 2021
Review period:
Every three years
Attachments:
Risk factors for complicated UTIs, Summary tables for empiric treatment, National cumulative antibiogram 2019
References:
CDC, IDSA, ESCMID, FDA standards
Year:
Not specified
Region / City:
Not specified
Subject:
Acute uncomplicated urinary tract infection (UTI) treatment
Document Type:
Patient Group Direction (PGD)
Author:
Not specified
Target Audience:
Healthcare professionals, community pharmacy staff
Effective Period:
Not specified
Approval Date:
Not specified
Revision Date:
Not specified
Note:
Year
Subject:
Healthcare, Infection Control
Document Type:
Medical Form
Organization / Institution:
Long-term Care Facility
Target Audience:
Healthcare professionals in long-term care facilities
Year:
2023
Region / city:
Wales
Topic:
Healthcare, Pharmaceutical Services, Urinary Tract Infections
Document Type:
Consultation Document
Organization / Institution:
AWTTC (All Wales Therapeutic and Toxicology Centre)
Author:
Alwyn Fortune
Target Audience:
Healthcare professionals, pharmacists, public health authorities
Effective Period:
Until consultation closing date
Approval Date:
Not provided
Amendment Date:
Not provided
Year:
2
Region / city:
San Diego, California
Theme:
Veterinary Medicine, Urinary Diseases, Extracorporeal Therapies
Document Type:
Fellowship Program Announcement
Organization / Institution:
University of California Veterinary Medical Center-San Diego (UCVMC-SD)
Author:
N/A
Target Audience:
Veterinarians
Period of Action:
2 years
Approval Date:
N/A
Modification Date:
N/A
Note:
Context
Note:
Year
Topic:
Urinary Tract Infection Management
Document Type:
Healthcare Plan
Year:
2026
Region / City:
United States
Topic:
Urgency urinary incontinence treatment
Document Type:
Clinical trial report
Institution:
Multiple U.S. medical centers
Authors:
Alexandra Rogers, MD; Rebecca McCrery, MD; Scott MacDiarmid, MD; Subhro Sen, MD; James Lukban, DO; Bilal Kaaki, MD; Andrew Shapiro, MD; Thomas Giudice, MD; John Nguyen, MD; Joseph Gauta, MD; Scott Serels, MD; Chris Threatt, MD; Jed Kaminetsky, MD; Vincent Lucente, MD; Sonia Dutta, MD; Peter Sand, MD; Kimberly Ferrante, MD
Study Design:
Prospective, multi-center, single-arm trial
Participants:
133 adults aged 18-80 with daily UUI episodes
Intervention:
Subcutaneous tibial neurostimulator (eCoin) implantation
Primary Outcome:
≥50% improvement in UUI episodes at 48 weeks
Secondary Outcomes:
3-day voiding diary data, patient-reported outcomes
Procedure Time:
20.8 minutes
Safety:
One serious device-related adverse event (localized infection resolved by explant)